Perfil dos pacientes com doenças inflamatórias intestinais na região sudoeste do Distrito Federal

Authors

  • Renata Filardi Simiqueli Durante
  • Marjorie Thomaz Moreira
  • Heleno Ferreira Dias
  • José Miguel Luz Parente
  • Pâmela Michelle Ernesto de Oliveira
  • Maria Liz Cunha de Oliveira

Keywords:

Inflammatory Bowel Diseases, Crohn's disease, Ulcerative colitis, Epidemiology

Abstract

outpatient clinic. Method: cross-sectional, descriptive epidemiological study with secondary data collection. The information was collected through an electronic medical record of the public health network. Results: 68 patients were selected, of whom 22 (32.4%) were male and 46 (67.6%) were female. At diagnosis, 48 (70.6%) patients had colitis, and 20 (29.4%) Crohn's.   In these, the most common pattern (30%) was colonic involvement, while in colitis, the majority (45.8%) presented pancolitis. Patients had, on average, 10 months of symptoms before diagnosis. The most widely used medicine in inflammatory bowel diseases was aminossaicylate. About 9% underwent surgery. No patient died. Conclusion: most of the findings were in line with current national studies. However, the heterogeneity of the disease and the lack of studies seem to be the main factors for divergences.

References

Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31886308/

Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg Clin North Am. 2019;99(6):1051–62. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31676047/

Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of in- flammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380–9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31596960/

Selinger CP, Ochieng AO, George V, Leong RW. The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison with Drug Metabolite Levels and Medication Possession Ratios. Inflamm Bowel Dis. 2019;25(5):919–24. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30265299/

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27914657/

Zaltman C, Parra RS, Sassaki LY, Santana GO, de Lourdes Abreu Ferrari M, Miszputen SJ, et al. Real-world disease activity and sociodemographic, clinical and treatment characteristics of mo- derate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol. 2021;27(2):208–23. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33510560/

Kotze PG, Underwood FE, Damião AOMC, Ferraz JGP, Saad-Hossne R, Toro M, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol [Internet]. 2020;18(2):304–12. Available from: https://doi.org/10.1016/j.cgh.2019.06.030

Calderón M, Minckas N, Nuñez S, Ciapponi A. Inflammatory Bowel Disease in Latin America: A Systematic Review. Value Heal Reg Issues. 2018;17:126–34. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29936359/

Kleinubing-Júnior H, Pinho M de SL, Ferreira LC, Bachtold GA, Merki A. Perfil dos pacientes ambulatoriais com doenças inflamatórias intestinais. ABCD Arq Bras Cir Dig (São Paulo). 2011;24(3):200–3. Disponível em: https://www.scielo.br/j/abcd/a/9fcn7WSgF4qYnMYV88BCqwb/abstract/?lang=pt

Quaresma AB, Kaplan GG, Kotze PG. The globalization of in- flammatory bowel disease: The incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol. 2019;35(4):259–64. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30973356/

Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA, Da Silva RM, et al. Inflammatory bowel disease in an underde- veloped region of Northeastern Brazil. World J Gastroenterol. 2015;21(4):1197–206. Disponível em: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC4306164/

Arantes JAV, dos Santos CHM, Delfino BM, da Silva BA, de Souza RMM, de Souza TMM, et al. Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease. J Coloproctology [Internet]. 2017;37(4):273–8. Available from: http://dx.doi.org/10.1016/j.jcol.2017.06.004

Salgado VCL, Luiz RR, Boéchat NLF, Leão IS, Do Carmo Schorr B, Parente JML, et al. Risk factors associated with inflammatory bowel disease: A multicenter case-control study in Brazil. World J Gastroenterol. 2020;26(25):3611–24. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366056/

Sairenji T, Collins KL, Evans D V. An Update on Inflammatory Bowel Disease. Prim Care - Clin Off Pract [Internet]. 2017;44(4):673–92. Available from: https://doi.org/10.1016/j. pop.2017.07.010

Lee DW, Koo JS, Choe JW, Suh SJ, Kim SY, Hyun JJ, et al. Diagnostic delay in inflammatory bowel disease increases the risk of in- testinal surgery. World J Gastroenterol. 2017;23(35):6474–81. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5643273/

Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn’s disease. Nat Rev Dis Prim [Internet]. 2020;6(1). Available from: http://dx.doi.org/10.1038/s41572-020-0156-2

Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med. 2021;8(December):1–24. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34988090/

Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;2020(8). Disponível em: https://pubmed.ncbi.nlm.nih.gov/32856298/

Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors as- sociated with the persistence of oral 5-aminosalicylic acid mo- notherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol. 2021;14:1–10. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34262610/

Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: Evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26(7):987–1003. Disponível em: https://pubmed.ncbi.nlm.nih.gov/17877506/

Ak A, Zhang D, Gordon M, Jk M, Ak A, Zhang D, et al. remission in Crohn ’ s disease ( Review ). 2016; Disponível em: https://pubmed.ncbi.nlm.nih.gov/27681657/

Seyedian SS, Nokhostin F, Malamir MD. A review of the diagno- sis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31406511/

Downloads

Published

2022-10-03

How to Cite

Durante , R. F. S., Moreira, M. T., Dias, H. F., Parente, J. M. L., Oliveira, P. M. E. de, & Oliveira, M. L. C. de. (2022). Perfil dos pacientes com doenças inflamatórias intestinais na região sudoeste do Distrito Federal. Revista De Divulgação Científica Sena Aires, 11(3), 370–379. Retrieved from https://rdcsa.emnuvens.com.br/revista/article/view/275

Issue

Vol. 11 No. 3 (2022): REVISA

Section

Original Paper

License

Copyright (c) 2024 Revista de Divulgação Científica Sena Aires

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  • Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.

  • Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.